Sight Sciences (NASDAQ:SGHT) Stock: Insider Brenton Taylor Sells 20,685 Shares

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Brenton Taylor sold 20,685 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $10.64, for a total value of $220,088.40. Following the completion of the transaction, the executive vice president owned 241,305 shares of the company’s stock, valued at $2,567,485.20. The trade was a 7.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Brenton Taylor also recently made the following trade(s):

  • On Friday, October 2nd, Brenton Taylor sold 2,988 shares of Sight Sciences stock. The shares were sold at an average price of $8.85, for a total transaction of $26,443.80.

Sight Sciences Trading Up 2.7%

NASDAQ:SGHT traded up $0.28 during trading hours on Wednesday, hitting $10.77. 335,567 shares of the company were exchanged, compared to its average volume of 285,342. The company has a fifty day simple moving average of $9.06 and a 200 day simple moving average of $6.25. The company has a current ratio of 5.04, a quick ratio of 4.72 and a debt-to-equity ratio of 0.71. Sight Sciences, Inc. has a one year low of $3.38 and a one year high of $11.60. The stock has a market capitalization of $598.60 million, a price-to-earnings ratio of -20.71 and a beta of 2.44.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of $24.92 million for the quarter, compared to analysts’ expectations of $23.55 million. Sight Sciences had a negative net margin of 32.13% and a negative return on equity of 43.91%. Sell-side analysts expect that Sight Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Sight Sciences during the 2nd quarter valued at $16,710,000. Pathstone Holdings LLC lifted its position in Sight Sciences by 30.2% during the third quarter. Pathstone Holdings LLC now owns 2,186,524 shares of the company’s stock valued at $20,466,000 after purchasing an additional 507,544 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Sight Sciences by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock worth $1,288,000 after purchasing an additional 40,346 shares during the last quarter. Renaissance Technologies LLC grew its position in Sight Sciences by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 293,358 shares of the company’s stock worth $1,106,000 after purchasing an additional 17,458 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Sight Sciences by 38.9% in the third quarter. Goldman Sachs Group Inc. now owns 278,044 shares of the company’s stock valued at $2,602,000 after acquiring an additional 77,917 shares during the period. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SGHT. UBS Group lifted their price objective on shares of Sight Sciences from $8.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, November 12th. HC Wainwright started coverage on Sight Sciences in a report on Thursday, October 15th. They set a “buy” rating and a $14.00 price objective on the stock. Wall Street Zen cut Sight Sciences from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (up from $9.00) on shares of Sight Sciences in a research note on Thursday, November 5th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a report on Wednesday, November 4th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.31.

Check Out Our Latest Stock Analysis on Sight Sciences

About Sight Sciences

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Read More

Insider Buying and Selling by Quarter for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.